Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers GDTC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.